CN113164460A - 咪唑喹啉化合物及其应用 - Google Patents

咪唑喹啉化合物及其应用 Download PDF

Info

Publication number
CN113164460A
CN113164460A CN201980068724.0A CN201980068724A CN113164460A CN 113164460 A CN113164460 A CN 113164460A CN 201980068724 A CN201980068724 A CN 201980068724A CN 113164460 A CN113164460 A CN 113164460A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
cancer
acceptable salt
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980068724.0A
Other languages
English (en)
Chinese (zh)
Inventor
L·杨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Birdie Biopharmaceuticals Inc Cayman Islands
Original Assignee
Birdie Biopharmaceuticals Inc Cayman Islands
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Birdie Biopharmaceuticals Inc Cayman Islands filed Critical Birdie Biopharmaceuticals Inc Cayman Islands
Publication of CN113164460A publication Critical patent/CN113164460A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201980068724.0A 2018-09-07 2019-09-05 咪唑喹啉化合物及其应用 Pending CN113164460A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862728556P 2018-09-07 2018-09-07
US62/728,556 2018-09-07
PCT/US2019/049784 WO2020051356A1 (en) 2018-09-07 2019-09-05 Imidazoquinoline compounds and uses thereof

Publications (1)

Publication Number Publication Date
CN113164460A true CN113164460A (zh) 2021-07-23

Family

ID=69722888

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980068724.0A Pending CN113164460A (zh) 2018-09-07 2019-09-05 咪唑喹啉化合物及其应用

Country Status (9)

Country Link
US (1) US20210214354A1 (https=)
EP (2) EP4306523A3 (https=)
JP (1) JP2022501327A (https=)
KR (1) KR20210074290A (https=)
CN (1) CN113164460A (https=)
AU (1) AU2019335366A1 (https=)
CA (1) CA3111786A1 (https=)
ES (1) ES2963112T3 (https=)
WO (1) WO2020051356A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899539B (zh) 2014-01-10 2021-11-09 博笛生物科技有限公司 用于免疫疗法的化合物和组合物
EP3166976B2 (en) 2014-07-09 2026-04-08 Birdie Biopharmaceuticals Inc. Anti-pd-l1 combinations for treating tumors
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
KR102726248B1 (ko) 2016-07-07 2024-11-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
IL312120B2 (en) 2017-06-23 2025-06-01 Birdie Biopharmaceuticals Inc Pharmaceutical compositions
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
CN115916342A (zh) * 2020-07-08 2023-04-04 普渡研究基金会 用于治疗纤维化疾病和癌症的化合物、组合物和方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007504232A (ja) * 2003-09-05 2007-03-01 アナディス ファーマシューティカルズ インク Ｃ型肝炎ウイルス感染治療用のｔｌｒ７リガンド及びそのプロドラッグの投与
US20080213308A1 (en) * 2004-09-14 2008-09-04 Nicholas Valiante Imidazoquinoline Compounds
US20170056391A1 (en) * 2014-07-09 2017-03-02 Birdie Biopharmaceuticals, Inc. Combination therapy compositions and methods for treating cancers
CN106943598A (zh) * 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-her2组合

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US689338A (en) * 1901-03-29 1901-12-17 Nat Faucet Company Tapping-bung.
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US8728486B2 (en) * 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
WO2013033345A1 (en) * 2011-08-30 2013-03-07 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
MX377916B (es) * 2014-04-22 2025-03-10 Hoffmann La Roche Compuestos 4-amino-imidazoquinolina.
EP3166976B2 (en) * 2014-07-09 2026-04-08 Birdie Biopharmaceuticals Inc. Anti-pd-l1 combinations for treating tumors
CN105732635A (zh) * 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007504232A (ja) * 2003-09-05 2007-03-01 アナディス ファーマシューティカルズ インク Ｃ型肝炎ウイルス感染治療用のｔｌｒ７リガンド及びそのプロドラッグの投与
US20100256169A1 (en) * 2003-09-05 2010-10-07 Anadys Pharmaceuticals, Inc. Administration of tlr7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus
US20080213308A1 (en) * 2004-09-14 2008-09-04 Nicholas Valiante Imidazoquinoline Compounds
US20170056391A1 (en) * 2014-07-09 2017-03-02 Birdie Biopharmaceuticals, Inc. Combination therapy compositions and methods for treating cancers
CN106943598A (zh) * 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-her2组合

Also Published As

Publication number Publication date
EP3846807B1 (en) 2023-08-02
KR20210074290A (ko) 2021-06-21
EP4306523A3 (en) 2024-01-24
EP3846807A4 (en) 2022-05-18
CA3111786A1 (en) 2020-03-12
JP2022501327A (ja) 2022-01-06
US20210214354A1 (en) 2021-07-15
EP3846807A1 (en) 2021-07-14
EP4306523A2 (en) 2024-01-17
ES2963112T3 (es) 2024-03-25
AU2019335366A1 (en) 2021-03-25
WO2020051356A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
CN113164460A (zh) 咪唑喹啉化合物及其应用
KR102164443B1 (ko) Ｉｄｏ 억제제로서 유용한 융합된 이미다졸 유도체
KR102083857B1 (ko) 신규 치환된 인다졸, 그의 제조 방법, 상기 신규 치환된 인다졸을 함유하는 제약 제제, 및 약물을 제조하기 위한 상기 신규 치환된 인다졸의 용도
CN103649089B (zh) 作为pi3k抑制剂的吡咯并三嗪酮
TWI652269B (zh) 氮雜吡啶酮化合物及其用途
CN102892765B (zh) 具有β2肾上腺素能激动剂及M3毒蕈碱拮抗剂的活性的环己胺衍生物
CN116574092B (zh) 苯并咪唑或氮杂苯并咪唑类化合物、其制备方法及其应用
CN117940432A (zh) 一种喜树碱类化合物、其制备方法和用途
US20200024277A1 (en) Triazolopyridines and triazolopyrazines as lsd1 inhibitors
JP2015533181A (ja) Ｐｉ３ｋ阻害剤としてのピロロトリアジノン誘導体
JP2025023928A (ja) 放出可能なｇｌｐ－１コンジュゲート
WO2020020385A1 (zh) 含三并环类衍生物抑制剂、其制备方法和应用
TW202400788A (zh) 用於靶向遞送治療劑的雙環雜環及其配體
CN102653522B (zh) ω-羧基取代的二苯基硫脲类化合物及其制备方法和用途
ES2580702A1 (es) Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
CN105384738B (zh) 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
CN111848528A (zh) 一种预防和/或治疗癌症的化合物及其制备方法和应用
CN110590898A (zh) 磷（膦）酰胺酯类化合物及其制备方法和用途
WO2025093058A1 (zh) 2-氧代吲哚啉类衍生物及其制备方法和应用
WO2022017442A1 (zh) 双功能蛋白降解靶向嵌合体类化合物及其制备方法和医药用途
CN108341774B (zh) 取代的喹啉酮类抑制剂
HK40101420A (en) Imidazoquinoline compounds and uses thereof
HK40057163A (en) Imidazoquinoline compounds and uses thereof
HK40057163B (en) Imidazoquinoline compounds and uses thereof
CN116120254B (zh) 13,14-双一氧化氮供体-β-榄香烯衍生物及其制备和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210723

WD01 Invention patent application deemed withdrawn after publication